Literature DB >> 15508076

Diagnosis and staging of hepatocellular carcinoma.

Jayant A Talwalkar1, Gregory J Gores.   

Abstract

The diagnosis of hepatocellular carcinoma (HCC) includes detection of the index lesion, staging of the lesion within the liver, and assessment for extrahepatic metastasis. HCC is a highly vascular neoplasm usually arising in a cirrhotic liver. Based on this concept, consensus criteria have been developed for the radiographic diagnosis of HCC. These include: (1) identification of a mass >2 cm in diameter in a cirrhotic liver in 2 imaging modalities, and (2) contrast enhancement on computed tomography, magnetic resonance, or angiography. A mass lesion within a cirrhotic liver in the presence of a serum alpha-fetoprotein level >400 ng/mL also is diagnostic. For lesions <2 cm in diameter, histological confirmation is required. Serum markers for the diagnosis of early HCC (<2 cm in diameter) have not been established. Staging HCC for metastases is insensitive and is based on conventional criteria (eg, pulmonary nodules, skeletal metastases, and lymphadenopathy). Additional diagnostic techniques based on cytological advances, genomics, and proteomics are needed for the diagnosis and staging of this highly malignant neoplasm.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15508076     DOI: 10.1053/j.gastro.2004.09.026

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008.

Authors:  Sean F Altekruse; Katherine A McGlynn; Lois A Dickie; David E Kleiner
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

Review 2.  Hepatocellular carcinoma: therapy and prevention.

Authors:  Hubert E Blum
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

Review 3.  [When only the pathologist may help. Limitation and possibilities of biopsies in Internal Medicine].

Authors:  R Knüchel-Clarke; H H Lutz; J Floege; N Marx; T H Brümmendorf; C Trautwein
Journal:  Internist (Berl)       Date:  2010-04       Impact factor: 0.743

Review 4.  Utility of screening for hepatocellular carcinoma among cirrhotics.

Authors:  Polly Niravath; Teresa Hayes; Susan Hilsenbeck
Journal:  Frontline Gastroenterol       Date:  2011-03-17

5.  Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.

Authors:  Christina Wich; Abbas Agaimy; Deike Strobel; Thaddäus Till Wissniowski; Arndt Hartmann; Matthias Ocker
Journal:  World J Gastroenterol       Date:  2010-07-28       Impact factor: 5.742

Review 6.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

7.  Single-nucleotide polymorphism at CYP27B1-1260, but not VDR Taq I, is possibly associated with persistent hepatitis B virus infection.

Authors:  Qianqian Zhu; Na Li; Qunying Han; Zhu Li; Guoyu Zhang; Fang Li; Pingping Zhang; Jinghong Chen; Yi Lv; Zhengwen Liu
Journal:  Genet Test Mol Biomarkers       Date:  2012-09

8.  Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma.

Authors:  Pisit Tangkijvanich; Duangporn Thong-Ngam; Varocha Mahachai; Apiradee Theamboonlers; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

Review 9.  Targeted therapy for hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-02       Impact factor: 46.802

10.  Evolving therapies in the treatment of hepatocellular carcinoma.

Authors:  Hans Christian Spangenberg; Robert Thimme; Hubert E Blum
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.